A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303
暂无分享,去创建一个
M. Tomonaga | S. Hanada | A. Utsunomiya | Yasuaki Yamada | K. Tobinai | K. Takatsuki | T. Hotta | M. Niimi | S. Ikeda | F. Kawano | M. Tara | M. Shimoyama | M. Kozuru | M. Sano | H. Fukuda | K. Araki | Other Members Of The Lymphoma Study Group of The J
[1] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[2] K. Tobinai. CHEMOTHERAPY OF ATL , 2003 .
[3] Y. Kodera,et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.
[4] M. Tomonaga,et al. Adult T‐cell leukemia cells over‐express the multidrug‐resistance‐protein (MRP) and lung‐resistance‐protein (LRP) genes , 1999, International journal of cancer.
[5] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[6] D. Huhn,et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study , 1997, Bone Marrow Transplantation.
[7] J. Tosswill,et al. Successful treatment of HTLV‐1‐associated acute adult T‐cell leukaemia lymphoma by allogeneic bone marrow transplantation , 1996, British journal of haematology.
[8] M. Tomonaga,et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[9] M. Kaplan,et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. , 1995, The New England journal of medicine.
[10] E. Macintyre,et al. Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa , 1995 .
[11] H. Taguchi. [Treatment of adult T-cell leukemia]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[12] Y. Ohashi,et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. , 1994, British Journal of Cancer.
[13] Y. Shimada,et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.
[14] R. Ohno,et al. Treatment of adult T‐cell leukemia/lymphoma with MST‐16, a new oral antitumor drug and a derivative of bis(2,6‐dioxopiperazine) , 1993 .
[15] T. Waldmann,et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. , 1993, Blood.
[16] K. Tobinai,et al. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. , 1992, Japanese journal of clinical oncology.
[17] M. Shimoyama. Treatment of patients with adult T-cell leukemia-lymphoma: an overview , 1992 .
[18] M. Shimoyama,et al. Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.
[19] K. Uozumi,et al. Expression of P-glycoprotein in adult T-cell leukemia cells. , 1990, Blood.
[20] K. Tajima. The 4th nation‐wide study of adult T‐cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features , 1990, International journal of cancer.
[21] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Tsugane,et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Y. Kodera,et al. [Phase II study of carboplatin in malignant lymphoma]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.
[24] M. Kikuchi,et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Tahara,et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. , 1987, Bone marrow transplantation.
[26] S. Kamihira,et al. Adult T cell leukemia with atypical surface phenotypes: clinical correlation. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Kanamaru,et al. [Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies]. , 1983, Gan to kagaku ryoho. Cancer & chemotherapy.
[28] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[29] M. Ichimaru,et al. Final Results of Cooperative Study of VEPA [Vincristine, Cyclophosphamide (Endoxan), Prednisolone and Adriamycin] Therapy in Advanced Adult Non-Hodgkin's Lymphoma: Relation Between T- or B-Cell Phenotype and Response , 1982 .
[30] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[31] S. Sekido,et al. Biologic activity of MCNU: a new antitumor agent. , 1979, Cancer treatment reports.
[32] J. Yodoi,et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. , 1977, Blood.
[33] J. Hilton,et al. Nitrosourea pharmacodynamics in relation to the central nervous system. , 1976, Cancer treatment reports.